Wolfe Research has upgraded Intellia Therapeutics (NTLA, Financial) from Peer Perform to Outperform, setting a new price target of $21. Analyst Andy Chen highlighted that the enterprise value of the company is currently perceived to be nearly zero, indicating a strong potential for growth that appeals to long-term investors.
Chen pointed out that even if the anticipated change in market sentiment happens later than expected, the current valuation of Intellia Therapeutics makes the stock attractive for an upgrade. This comes as the company experiences a rapid enrollment rate in its Phase 3 trial for nexiguran ziclumeran, targeting hereditary ATTR amyloidosis with polyneuropathy. According to the analyst, this swift enrollment is a positive indicator of the company's future revenue potential.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 23 analysts, the average target price for Intellia Therapeutics Inc (NTLA, Financial) is $43.78 with a high estimate of $106.00 and a low estimate of $8.00. The average target implies an upside of 433.93% from the current price of $8.20. More detailed estimate data can be found on the Intellia Therapeutics Inc (NTLA) Forecast page.
Based on the consensus recommendation from 28 brokerage firms, Intellia Therapeutics Inc's (NTLA, Financial) average brokerage recommendation is currently 2.1, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for Intellia Therapeutics Inc (NTLA, Financial) in one year is $28.51, suggesting a upside of 247.68% from the current price of $8.2. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the Intellia Therapeutics Inc (NTLA) Summary page.
